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1. Introduction 
1.1 Marek’s disease virus (MDV) 
Marek’s disease virus (MDV) belongs to the alphaherpesvirus family, like Herpes simplex 
viruses 1 and 2 (HSV-1 and HSV-2) and varicella zoster virus (VZV). Marek’s Disease Virus 
(MDV) is the etiologic agent of Marek’s Disease (MD), a highly contagious malignant 
lymphoma of chickens. (Morimura, et al. 1998).  
Marek’s Disease (MD) was first described by József Marek in 1907 as fowl paralysis caused 
by mononuclear infiltration into the sciatic nerve plexi (Marek, 1907). Marek’s Disease (MD) 
is a lymphoproliferative and neuropatic disease of domestic chickens and, less commonly, 
turkeys and quails (Payne & Venugopal, 2000). 
Generally, four different clinical forms of the disease are recognized in flocks infected with 
MDV: A) Classical or neuronal form; B) Acute form; C) Transient paralysis and D) Acute 
mortality syndrome. 
1.2 MDV life cycle 
The infection occurs by inhalation of infected dust (Beasley, et al. 1970) in the poultry house 
environment contaminated with the viruses shed from the feather follicle epithelium of 
infected birds. According to the current model of MDV pathogenesis, it is thought that the 
virus is transported by macrophages from the lungs to the lymphoid tissues of the spleen, 
thymus and the bursa of Fabricius, where virus targets the lymphocyte subsets, the major 
cells of the host immune system (Fig. 1). These cells could transport MDV to the lymphoid 
tissues via the lymph or blood, where it can be detected as early as 18 h post-infection 
(Adldinger & Calnek, 1973) 
Calnek and coworkers (Calnek, 1985; Calnek, 1986; Schat, 1987) developed a model for the 
pathogenesis of MD in the early 1980s which remains valid (Fig. 2). MDV is first detected in 
the spleen 3 days post-exposure after exposure by inhalation. The virus causes an early 
cytolytic infection in B cells, which are presumed to be the primary target for viral 
replication (Schat et al., 1980; Calnek et al., 1982; Shek et al., 1983). Resting T cells are 
refractory to infection; successively, T cells become activated and susceptible to MDV 
infection (Calnek et al,. 1984 a, b).  
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Fig. 1. Pathogenesis of MD. Feather follicle epithelium (FFE); B-cells (B); T-cells (T); 
macrophages (M) (Modified from: Nair, 2005). 
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Fig. 2. Sequential events in lymphocyte infections with MDV (Modified from: Calnek, 
1985) 
It was hypothesized (Schat & Xing,  2000; Schat, 2001) that, during the lytic infection, the 
MDV transfer from B to T cells may be facilitated by the production of vIL-8. This is a CXC 
chemokine and it was described as a homologue of IL-8 (vIL-8) (Parcells et al., 2001); vIL-8 is 
the first reported CXC chemokine encoded by an alphaherpesvirus (Liu et al., 1999). The 
majority of these T cells are CD4+TCR1+, but a small percentage of infected cells are 
CD8+TCR2+ (Sugano et al., 1987; Martins-Green, 2001). Moreover, MDV-driven tumors are 
dominated by a highly restricted number of CD4+ clones. Further, the responding CD8+ T 
cell infiltrate is oligoclonal, indicating recognition of a limited number of MDV antigens 
(Mwangi et al., 2011). 
These early cytolytic events result in atrophic changes in the bursa of Fabricius and 
thymus, leading to severe debilitation of the immune system and marked 
immunosuppression. One week post-infection, when virus levels peak, MDV switches 
from early cytolytic to latent infection, probably due to cell-mediated immune responses 
(Buscaglia et al., 1988; Schat & Xing, 2000). During latency, clinical signs of the infection 
diminish, productive viral antigen cannot be detected in the bursa, thymus and spleen, 
and within 2 weeks the lymphocyte populations in the bursal follicles and thymic cortex 
return to normal. 
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1.3 Defence  mechanisms against MDV infection 
1.3.1 Nonspecific immune responses 
Against MDV infections, the organisms establish both nonspecific and specific immune 
responses. The cells involved in these responses are NK cells and macrophages.  It has 
been hypothesized that avian NK cells are able to recognize target cells as mammalian 
NK cells do (Kaufman, 1996; Kaufman & Salomonsen, 1997; Kaufman & Venugopal, 
1998). Macrophages play an important role in resistance to MDV infection both in vitro 
and in vivo; their depletion leads to a lower immunity versus MD and reduces protective 
efficacy of vaccination (Gupta et al., 1989). They are thought to be critical during the 
early stages after MDV infection, but are also important during the later stages of 
pathogenesis (Calnek, 2001); they limit MDV replication or have a detrimental role (Lee. 
et al., 1978 a,b).  
Macrophages are involved in virus phagocytosis, but no replication, or antigenic changes at 
the cell surface have been observed (Haffer & Sevoian, 1979; Haffer et al., 1979). MDV 
antigen expression was not evident after co-culturing of either bone marrow-derived 
macrophages or macrophage cell lines with MDV-infected lymphocytes, suggesting the 
requirement for in vivo conditions. These data indicate that macrophages could be a primary 
target for cytolytic infection in vivo, in addition to facilitating transportation of the virus, as 
proposed by Calnek (Calnek, 2001). Macrophages from MDV-infected chickens are also able 
to inhibit the DNA synthesis of MD lymphoblastoid cell lines (Lee et al., 1978 b) and 
suppress the mitogen response of T lymphocytes (Lee et al., 1978 a,b); these effects have also 
been found in macrophages isolated from uninfected chickens (Sharma, 1980; Von Bulow & 
Klasen, 1983).  
Macrophages are also able to produce large quantities of Nitric Oxide (NO) (Hussain & 
Qureshi, 1997); depletion of these cells causes the suppression of NO production and so 
the increase of viral load in the blood, tumour incidence and tumour load (Rivas  et al., 
2003). Moreover, in addition the high levels of IL-1, IL-6, IL-12, iNOS, and type 1 and 2 
IFNs, the relative expression levels of IL-4, IL-10, and IL-13 were significantly 
upregulated in the infected chickens during the lytic phase of infection compared to 
uninfected controls. This observation suggests that an immune response with a Th-2 
characteristic is induced by a very virulent plus MDV strain during the lytic phase of 
infection, and there is no significant MDV-specific immune response in the latent phase 
of infection (Heidari et al., 2008) 
1.3.2 Specific immune responses 
Specific immune responses are antigen-dependent and require lymphocyte activation to 
produce specific antibodies and antigen-specific CD4+ and CD8+ T cells.  Cell-mediated 
immune responses (CMI) and virus neutralizing antibodies are important in herpesvirus 
infections in general (Mester & Rouse, 1991) and have been described after natural infection 
with oncogenic MDV and after inoculation with vaccine strains. It was suggested that CTL 
(Cytotoxic T Limphocytes) responses are also important for the elimination of MDV-infected 
cells (Ross, 1977; Kodama et al., 1979). Although immune defences against infected cells are 
predominantly mediated by CTL, humoral immune responses also play an important role in 
herpesvirus infections (Medveczky et al., 1998). Antibodies to the virus envelope neutralise 
viral infectivity, kill lytically infected cells by antibody-dependent cell cytotoxicity (ADCC), 
and protect against reinfections with EBV (Chubb & Churchill, 1969).  
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1.3.3 Induction of apoptosis 
Apoptosis of virus-infected cells can be beneficial to the host if cells are eliminated before 
virus assembly. It is therefore not surprising that certain viruses code for proteins inhibiting 
apoptosis during the early phase of replication but facilitate the process during the later 
stages of replication. Apoptosis occurs during MDV infection in CD4+CD8+ thymus tissues 
in the first week after infection (Morimura et al., 1996), during the second week in CD4+ T 
cells in peripheral blood (Morimura et al., 1995) and spleen cells from chickens 7 days post 
infection with the JM-16 strain of MDV (Schat & Xing, 2000). However, it is likely that the 
Meq protein is responsible for the prevention of apoptosis. This protein is expressed in most, 
if not all, MD tumour cell lines and overexpression of meq in the rodent cell line Rat-2 
caused transformation of these cells. The transformed cells became highly resistant to the 
induction of apoptosis (Liu  et al., 1998). It is of interest to note that meq is transcribed during 
the lytic infection without an apparent effect on apoptosis. However, the regulation of meq 
transcription is very complex and alternate splicing has been described (Peng & Shirazi, 
1996). Recently was described that the Meq oncoprotein interacts directly with p53 and 
inhibits p53-mediated transcriptional activity and apoptosis, providing a valuable insight 
into the molecular basis for the function of meq in MDV oncogenesis (Deng et al., 2010) 
Moreover, expression of pp38 in tumour cells may be correlated with the induction of 
apoptosis (Schat & Xing, 2000). This hypothesis is interesting in view of the finding that 
pp38 expression in MD tumour cell lines is generally low and is apparently inversely related 
to the expression of meq and a small RNA antisense to ICP4 (Ross et al., 1997). Expression of 
pp38 in tumour cell lines can be upregulated by transfection with ICP4 (Pratt et al., 1994). 
There are very recent data that involve microRNAs (highly conserved among different field 
strains of MDV1), and they are expressed in lytic and latent infections and in MDV1-derived 
tumors. This evidence suggests that these small molecules are very important to the virus, 
and that they play some roles in immune evasion, anti-apoptosis, or proliferation (Burnside 
& Morgan, 2011). All these data suggest that the fate of tumour cells depends on an intricate 
balance between the expression and phosphorylation of Meq (Liu et al., 1999), pp38, ICP4 
and the small antisense RNA to ICP4 (Gimeno & Cortes, 2010).  
1.3.4 MD vaccination 
It is thought that the economic impact of MD on the global poultry industry accounts for at 
least US $1 bn yearly (Nair, 2005).  The first MDV vaccine was obtained with an oncogenic 
strain repeatedly passaged in vitro; it was able to prevent MD tumors in chickens challenged 
with oncogenic MDV (Churchill & Chubb, 1969) but not to prevent the infection with field 
viruses. The first attenuated vaccine was used in the UK in 1970 but was quickly replaced by 
an HVT vaccine (Turkey Herpes Virus) (Witter et al., 1970). Introduction of HVT as a live 
vaccine resulted in significant reduction of MD incidence and was extensively used because 
of its efficacy and economical production in tissue culture (Okazaki et al., 1970; Purchase & 
Okazaki, 1971). However, within 10 years, new outbreaks of clinical MD occurred in 
vaccinated flocks (Eidson et al., 1978; Witter et al., 1980) and vvMDV isolated from these 
birds had a greater pathogenic effect than field viruses present before vaccine introduction 
(Witter, 1983). It was probably due to imperfect vaccination practices and, in some countries, 
wrong hygienic conditions that led to reservoirs of viruses in poultry houses (Bourne, 1996). 
In response to the increasing number of MD outbreaks in vaccinated flocks, in the 1980s, 
new vaccines based on the non-oncogenic serotype-2 MDV were introduced in bivalent 
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combination with HVT (Calnek et al., 1983; Witter et al., 1984). The use of polyvalent vaccine 
provided a better protection against MDV challenge (Witter, 1992). This strategy was 
initially effective, but in the 1990s new and more virulent MDV pathotypes (vv + MDV) 
were isolated from flocks vaccinated with bivalent vaccines. In Europe, the problems have 
been less severe and in the Netherlands a very effective MDV vaccine, based on a weakly 
oncogenic serotype-1 MDV (CVI988), has been available (Rispens et al.,1972; Geerligs et al., 
1999;  Witter, 2001, Baigent et al., 2006; Schat & Baranowski, 2007). All these vaccination 
strategies are unfortunately due to the rapid variability of virus; vaccines are poorly 
effective in preventing infection in time (Gimeno, 2008). 
1.3.5 Mechanisms of Herpesviruses infection 
Attachment of HSV to cells occurs upon binding of gC to GAGs that decorate heparan 
sulphate or chondroitin sulphate (Spear et al., 1992). This step enhances HSV infectivity, but 
is not an absolute requirement, as cells defective in heparin sulphate and chondroitin 
sulphate exhibit a 100-fold reduced susceptibility to infection, yet can be infected 
(Gruenheid et al., 1993). A large variety of viruses use heparan sulphate proteoglycans as 
receptors; their broad expression argues that they cannot be responsible for any specific 
viral tropism. Herpes simplex virus type 1 (HSV-1) infects a wide range of cells and causes 
disease in a variety of different tissues.  
Electron microscopy studies suggested that this virus enters host cells by means of either 
endocytosis or fusion between the membranes of the virus and the cell (Hodnichak et al., 
1984). The envelope of the HSV-1 virion contains at least ten different viral glycoproteins, 
several of which project as distinct spikes from the membrane surface and are likely to 
interact sequentially or simultaneously with different binding sites on the cell surface (Fuller 
& Lee, 1992; Herold et al., 1994). The initial attachment of virions to cells is shown to be 
mediated independently by interactions of either glycoprotein C (gC) or glycoprotein B (gB) 
with heparan sulphate moieties of cell surface proteoglycans (Campadelli-Fiume et al., 1990; 
Spear et al., 1992; Shieh et al., 1992; Gruenheid et al., 1993; Herold et al., 1994; Trybala et al., 
1994).  
Heparin, an anionic related glycosaminoglycan, has been demonstrated to block HSV-1 
adsorption to cells (WuDunn & Spear, 1989). There is also evidence that glycoprotein D (gD) 
may interact with its own cell receptor (Johnson et al., 1990), and oligomers of glycoprotein 
H (gH) and glycoprotein L (gL) are also known to be required for HSV-1 penetration (Fuller 
& Lee, 1992; Forrester et al., 1992; Roop et al., 1993). Moreover, it has been suggested that the 
low-density lipoprotein receptor present in coated pits may interact with domains in gB, gC 
or gD allowing the virions to penetrate by an endocytosis process (Becker et al., 1994).  
Heparan sulphate, the primary cell surface receptor for HSV-1, is a ubiquitous and 
multifunctional constituent of most mammalian cell plasma membranes and of extracellular 
matrices, and has been also identified as a binding site for human and bovine lactoferrin (Ji 
& Mahley, 1994; Mann et al., 1994; Wu et al., 1995).  The evidence that heparan sulphate 
proteoglycans and the low density lipoprotein receptor-related protein are capable of 
binding to lactoferrin, and acting as receptors for initial cell-HSV-1 interactions, suggested 
the idea that lactoferrin could interfere with early events of viral infection.  
In previous studies the efficacy of Lactoferrin and Ovotransferrin to prevent the in vitro 
infection of chicken cell lines with MDV was demonstrated (Giansanti et al., 2002, 2005). The 
efficacy of Lactoferrin and its derivative peptides against a variety of viruses as rotavirus 
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and HSV was also demonstrated (Gruenheid et al., 1993; Siciliano et al., 1999; Spear et al., 
2000; Superti et al., 2001)  
2. Lactoferrin 
Lactoferrin (Lf) is a non-haem iron-binding protein that is part of the transferrin protein 
family, along with serum transferrin (sTf), ovotransferrin (Otrf), melanotransferrin and the 
inhibitor of carbonic anhydrase. Lf is produced by mucosal epithelial cells in various 
mammalian species, including humans, cows, goats, horses, dogs, and several rodents 
(González-Chávez et al., 2009). This glycoprotein has protective functions and it is found in 
mucosal secretions, including tears, saliva, vaginal fluids, semen (van der Strate et al., 2001), 
nasal and bronchial secretions, bile, gastrointestinal fluids, urine (Öztas & Özgünes, 2005) 
and, most highly, in milk and colostrum (up to 7 g/L) (Rodriguez et al., 2005) making it the 
second most abundant protein in milk after caseins (Connely, 2001). It can also be found in 
bodily fluids such as blood plasma and amniotic fluid, and in considerable amounts in 
secondary neutrophil granules (15 μg/106 neutrophils) (Bennett & Kokocinski, 1987; 
González-Chávez et al., 2009), where it plays a significant physiological role. Lf possesses a 
great iron-binding affinity with the ability to retain the metal over a wide pH range (Aisen & 
Leibman, 1972) including extremely acidic pH. It also exhibits a great resistance to 
proteolysis. In addition to these differences, Lf net positive charge and its distribution in 
various tissues make it a multifunctional protein (Valenti & Antonini 2005; Baker & Baker, 
2009).  
2.1 Lactoferrin structure 
Lf is an 80 kDa glycosylated protein of ca. 700 aminoacids (711 aa for hLf and 689 aa bLf) 
with high homology among species. It is a simple polypeptide chain folded into two 
symmetrical lobes (N and C lobes) which are highly homologous with one another (33–41% 
homology) (Anderson et al., 1987, 1989; Baker, 1994; Moore et al., 1997; Sharma et al., 1998; 
Baker & Baker, 2009).  These two lobes are connected by a hinge region containing parts of 
an ǂ-helix between residues 333 and 343 in human Lf (hLF), which provides additional 
flexibility to the molecule. The polypeptide chain includes amino acids 1–332 for the N lobe 
and 344–703 for the C lobe, and is made up of ǂ-helix and ǃ-pleated sheet structures that 
create two domains for each lobe (domains I and II) (Moore et al., 1997). Each lobe can be 
further divided into two subdomains (N1 and N2 in the N-lobe and C1 and C2 in the C-
lobe) that form a cleft inside of which the iron is bound. The subdomain N1 contains 
residues 1-90 and 251-333, while N2 contains the residues 91-250) (Baker et al., 1998; Moore 
et al., 1997; Baker & Baker, 2009). Each lobe can bind a metal atom in synergy with the 
carbonate ion (CO32−). Lf notably binds Fe2+ and Fe3+ ions, but also Cu2+, Zn2+ and Mn2+ ions 
(Aisen & Harris, 1989; Baker et al., 1994, 2005; Baker & Baker, 2009). 
2.2 Antinfective activities of Lf 
Lf is involved in several physiological functions, including: regulation of iron absorption in 
the bowel; immune response; and antioxidant, anticarcinogenic and anti-inflammatory 
properties. Protection against microbial infection is the most widely studied function to date 
(Sanchez et al., 1992; Brock, 1995; Lonnerdal & Iyer; 1995; Vorland, 1999; Brock, 2002; Valenti 
& Antonini, 2005; Baker & Baker, 2009; Leboffe et al., 2009). The antimicrobial activity of LF 
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is mostly due to two different mechanisms: the first one is iron sequestration in sites of 
infection, which deprives the microorganism of this metal, thus creating a bacteriostatic 
effect. The other mechanism is the direct interaction of LF with the infectious agents. 
Positively charged amino acids of LF can interact with anionic molecules on some bacterial, 
viral, fungal and parasite surfaces, causing cell lysis (Bullen, 1981; Braun & Braun, 2002; 
Valenti & Antonini, 2005). Considering the physiological capabilities of Lf in host defence, in 
addition to current pharmaceutical and nutritional needs, Lf is considered to be a 
nutraceutical, and for several decades investigators have searched for the most convenient 
way to produce it (González-Chávez et al., 2009).  
Molecular mechanims of Lf antiparasitic activity are more complex. Antiparasitic activities 
of Lf often appear to involve interference with iron acquisition by some parasites, e.g. 
Pneumocystis carinii, while Lf appears to act as a specific iron donor in other parasites such as 
Trichomonas foetus; in the latter case, Lf could be expected to enhance infection. 
Preincubation of Toxoplasma gondii and Eimeria stiedai sporozoites with an Lf-derived 
peptide, lactoferricin, reduces their infectivity in animal models. Lf antiparasitic activity is 
also sometimes mediated by interaction with host cells. Thus, iron-saturated Lf enhances 
intramacrophage killing of T. cruzi amastigotes and decreases intra-erythrocytic growth of 
Plasmodium falciparum. Lf is able to inhibit the invasion of cultured cells by Plasmodium spp. 
sporozoites through specific binding to HS. In the case of Plasmodium berghei, Lf reduces 
invasion by inhibiting the binding of the plasmodial CS protein, with or without HS, 
suggesting the possibility that Lf can also bind to the same site on LDL receptor-related 
protein (LRP) as the CS protein (see Leboffe et al., 2009). 
The antiviral activity of hLf was firstly demonstrated in mice infected with the polycythemia-
inducing strain of the Friend virus complex (FVC-P) (Lu et al., 1987). Since 1995, potent 
antiviral activity of hLf and bLf has been demonstrated against both enveloped and naked 
viruses, like Cytomegalovirus (CMV) (Harmsen et al., 1995; Andersen et al., 2001), Herpes simplex 
virus (HSV) (Marchetti et al., 1996, 1998; Siciliano et al., 1999; Valenti & Antonini, 2005), Human 
immunodeficiency virus (HIV) (Swart et al., 1996; Puddu et al., 1998), as well as Human hepatitis C 
(HCV) and human hepatitis B (HBV) viruses (Ikeda et al., 1998; Hara et al., 2002). 
3. Ovotransferrin 
Ovotransferrin is the iron-binding glycoprotein belonging to the family of transferrin iron-
binding glycoproteins, found in avian egg white and in avian serum. Contrary to the 
mammalian genome, the avian genome contains only one transferrin gene which is 
expressed both in liver and oviduct, being present in most bodily fluids, including serum 
and egg albumen where its concentration reaches values as high as 12 g/L (Stevens, 1991). 
The expression of this avian transferrin gene is modulated by iron level in liver and by 
steroid hormones in oviduct.  The liver and  oviduct products are known as avian serum 
transferrin and ovotransferrin, respectively (Dierich et al., 1987). Avian serum transferrin is 
devoted to iron transport and delivery, while ovotransferrin displays protective functions, 
similarly to mammalian lactoferrin. 
3.1 Ovotransferrin structure 
Strong similarities could be observed between mammalian serum transferrin, lactoferrin 
and ovotransferrin; despite few differences in aminoacids sequences, the overall 3D 
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structure is strictly conserved. The polypeptide chain is folded into two lobes, each 
containing a single iron-binding site. The two lobes have very similar structures, as expected 
from the sequence identity of 37.4% with mammalian lactoferrin (Jeltsch & Chambon, 1982; 
Williams et al., 1982). The polypeptide chain includes amino acids 1-329 for the N lobe and 
330-686 for the C lobe (Thakurta et al., 2003). Interestingly, the two half molecules of 
ovotransferrin corresponding to the N-terminal and C-terminal lobes, obtained by a limited 
proteolysis procedure, have the ability to re-associate non-covalently in solution (Oe et al., 
1988). Most of the secondary structural elements are comparable between the two lobes. The 
main differences between the two lobes are in the loop regions, as expected by sequence 
insertions and deletions in the primary structure. Each lobe is comprised of two distinct, 
similar-sized ǂ/ǃ sub-domains (N-terminal lobe with N1 and N2 subdomains; C-terminal 
lobe with C1 and C2 subdomains). The two sub-domains are linked by two antiparallel ǃ-
strands that allow them to adopt either open or closed conformations. Iron (III) ions bound 
to Otrf are hexacoordinated, and the two iron-binding sites are located in the inter-sub-
domain cleft of each lobe (Kurokawa et al., 1995; Kurokawa et al., 1999; Mizutani et al., 1999, 
2000; Lindley et al., 1993; Kuser et al., 2002; Thakurta et al., 2003) being very similar each 
other and to those reported for human lactoferrin and for human serum transferrin 
(Anderson et al., 1989).  
3.2 Antinfective activities of ovotransferrin 
Ovotransferrin antibacterial activity partially depends on its ability to bind and sequester 
iron, essential for bacterial growth (Alderton et al., 1946, Bullen et al,. 1978). This activity is 
bacteriostatic, and the effect can be reversed by addition of exogenous iron ions. Other 
studies suggested that the antibacterial activity of Otrf is not simply due to the removal of 
iron from the medium, but probably involves further, more complex mechanisms (Ibrahim 
et al., 2000). Ovotransferrin, as well as serum transferrin and lactoferrin, were also shown to 
permeate the E. coli outer membrane and to access the inner membrane, where they caused 
permeation of ions in a selective manner (Aguilera et al., 2003). The importance of the 
presence of cationic sequences on the surface of Otrf in exploiting the antibacterial activity 
has been clearly pointed out by Ibrahim (Ibrahim et al., 1998) using a peptide called OTAP-
92 obtained by limited proteolysis, consisting of 92 amino acid residues located within the 
109–200 sequence at the lip of the N2 domain of the N lobe  
In relation to the antifungal activity of Otrf, a direct interaction of iron-loaded protein with 
Candida cells has been reported (Valenti et al., 1985), like bovine and human lactoferrin 
(Leboffe et al., 2009). The inhibiting activity of Otrf was tested against one hundred strains of 
Candida spp; the anti-mycotic effect was not coupled to iron sequestration, but rather 
related to Otrf binding on the Candida cell surface (Valenti et al., 1985; Valenti et al., 1986; 
Superti et al., 2007 a, b). 
Ovotransferrin’s antibacterial activity was established many years ago while the antiviral 
activity of Otrf was demonstrated only recently towards the Marek’s disease virus (MDV), 
an avian herpesvirus (Giansanti et al., 2002). In addition, it was found that following 
infection with MDV on Chichen Embryo Fibroblasts (CEF), a variety of host genes were 
transcribed, including ovotransferrin (Morgan et al., 2001). Moreover, in vitro viral infection 
of chicken embryo fibroblasts caused a slight increase of ovotransferrin release, whereas 
viral re-infection of lymphoblastoid cells in vitro caused a remarkable ovotransferrin release 
in a virus concentration-dependent manner (Giansanti et al., 2007). Finally, the production of 
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nitric oxide (NO), a molecule naturally exerting an antiviral activity, was observed in 
MDCC-MSB1 (Chicken hematopoietic lymphoblastic cell line) following reinfection and/or 
Otrf and lactoferrin (Lf) or following treatment with the cytokines IL-8 and IFN-), thus 
suggesting a possible role as a complementary or alternative strategy against MDV infection 
spread (Giardi et al.,  2009). 
4. Antiviral activity of intact lactoferrin 
The antiviral effect of lactoferrin was first believed to be linked to its iron-binding property, 
similarly to other iron-chelating substances known as inhibitors of herpesvirus ribonucleotide 
reductases (Spector et al., 1989, 1991). In contrast, lactoferrin effect towards HSV-1 infection 
does not appear related to iron-withholding since no significant differences in the HSV-1 
inhibition were found between lactoferrins in apo- and iron-saturated form. The infection 
inhibition occurs during the very early phases of the viral multiplication cycle, since the 
highest inhibitory effect took place when lactoferrin was added during the attachment step. In 
fact, the binding of [35S]methionine-labelled HSV-1 virions to Vero cells was strongly inhibited 
when bLf was added. bLf interacts with both Vero cell surfaces and HSV-1 particles, 
suggesting that the hindrance of cellular receptors and/or of viral attachment proteins may be 
involved in its antiviral mechanism (Marchetti et al., 1996). The antiviral effect of lactoferrin 
correlates well with its affinity for the virus receptor binding sites. In fact, polyanionic 
glycosaminoglycan chains of heparan sulphate and apo-lipoprotein-E receptor have been 
shown to interact with highly cationic lactoferrin (Pierce et al., 1991).  
Consequently, it can be assumed that the capability of lactoferrin to inhibit HSV-1 infection 
at the level of viral attachment may rely to a large extent on its competitive interaction with 
cell receptors for HSV-1 which can hinder the binding of the virus attachment proteins. bLf 
is a better inhibitor than hLf, with a selectivity index being over 10-fold higher. This effect of 
bLf on HSV-1 infection probably involves more than a simple mechanism of interference at 
the level of cell receptors. A direct interaction of bovine lactoferrin with virus particles has 
been demonstrated by the findings that virus binds efficiently to bLf immobilized on a solid-
phase surface, as revealed by an ELISA method, and causes the rapid agglutination of bLf 
coated latex beads. It can be put forward that the lower activity of hLf against HSV-1 (or the 
absence of antiviral activity anti HSV-1 of the hen’s Ovotransferrin), as compared with that 
of bLf, is linked to differences in the molecular structure. Bovine lactoferrin is 69% identical 
to human lactoferrin (49% to Ovotransferrin), but, in spite of this high degree of similarity, 
their comparison shows that the glycan chains of the molecules and the number of 
disulphide bridges vary (Metz-Boutigue et al., 1984; Pierce et al., 1991). These variations are 
likely to contribute to the differences in the functional domains responsible for the binding 
properties of the lactoferrins to host cells and viral particles (Marchetti et al., 1996). 
4.1 Antiviral activity of lactoferrin peptides 
Antimicrobial peptides are produced by a wide variety of organisms as their first line of 
defense, the so-called innate immune strategy (Hancock, 2001).  Hundreds of such peptides 
have been isolated (Hancock  & Chapple, 1999), suggesting their importance in the innate 
immune system (Hancock & Diamond, 2000). Antimicrobial peptides are typically relatively 
short (12 to 100 amino acids), positively charged, amphiphilic and have been isolated from 
single-celled microorganisms, amphibians, birds, fish plants and mammals, including man 
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(Wang & Wang, 2004; Ganz, 2005). Several antimicrobial peptides have been shown to also 
inhibit viral infection. The spectrum of viruses that are affected primarily comprises the 
enveloped RNA and DNA viruses. In most cases it has been concluded that antiviral activity is 
exerted at a very early stage in the viral multiplication cycle, either by direct action of the 
peptides on the virus itself (Aboudy  et al., 1994; Robinson  et al., 1998) or at the virus-cell 
interface (Belaid et al., 2002). It has also been demonstrated that antimicrobial peptides regulate 
multiple cellular genes (Scott et al., 2002), findings which support peptide stimulation of the 
cellular immune response (Andersen et al., 2004). A reasonable hypothesis is that the products 
of a subset of these peptide-upregulated genes are able to suppress endotoxic responses that 
lead to production of pro-inflammatory cytokines while upregulating other genes assisting in 
resolving infections (Bowdish et al., 2005 a, b; Bowdish & Hancock, 2005;  Jenssen, 2005). 
bLf derived peptide lactoferricin B (bovine lactoferrin fragment bLf17–41), generated from 
pepsin digestion of such protein, besides activities reported against bacteria, fungi, 
protozoa, and tumors (Bellamy et al., 1992; Yoo  et al.,   1998; Omata  et al., 2001), exerts a 
small, although significant, antiviral activity towards herpes simplex virus (Andersen  et al., 
2004), human cytomegalovirus (Andersen  et al., 2001), and adenovirus (Di Biase et al., 2003). 
In solution, lactoferricin B adopts a twisted beta-sheet structure that becomes markedly 
amphipathic with the hydrophobic groups lining up on one face of the peptide, while the 
opposite face contains most of the basic residues (Vogel  et al., 2002; Zhou  et al.,2004) 
possibly interacting with glycosaminoglycan viral receptors. The N-terminus of lactoferrin 
binds to surface glycosaminoglycans (Mann et al., 1994; Wu et al., 1995), which are initial 
binding sites for HASV-1 virus (WuDunn & Spear, 1989; Roderiquez et al., 1995) and a direct 
lactoferrin interaction with viral particles has been hypothetized (Marchetti et al., 1996; 
Swart et al., 1996; Yi et al., 1997). In an attempt to identify other lactoferrin amino acid 
sequences contributing to the antiviral activity, the antiviral activity of a library of peptide 
fragments, derived from the tryptic digestion of bLf, was analysed towards HSV1, a 
susceptible enveloped virus. The pool of fragments deriving from tryptic digestion of bLf 
showed antiviral activity toward HSV-1, suggesting that the inhibition of viral infection 
could not be exclusively linked to native, undigested bLf (Siciliano et al., 1999).  
Moreover, the protective effect towards HSV-1 infection possessed by low and high molecular 
weight peptides, deriving from tryptic digestion of bLf, was analyzed. Among high molecular 
weight peptides, the fraction with amino acid sequence 1–280, belonging to the N-lobe, was 
ten-fold more effective towards HSV-1 infection than the fraction representing the whole C-
lobe. On the other hand, the fraction 1-280 was still six-fold less active than native bLf, which 
exerted the maximal antiviral activity. The different antiviral activity of the C-lobe and N-lobe 
toward HSV-1 cannot be explained on the basis of their different glycosylation sites (three 
glycosylation sites present in C-lobe while only one in N-lobe) since their removal from 
undigested bLf did not affect anti HSV-1 activity (Sicilano et al., 1999). The absence of antiviral 
activity of the large fraction with amino acid sequence 86–258, which corresponds to the N2 
domain, has been correlated to the lack of amino acid sequences 1–85 and/or 259–280, present 
in the effective fraction 1–280 which contains the N2 domain together with part of the N1 
domain. Furthermore, it was observed that, among the low molecular weight fragments, only 
the association of two small peptides (ADRDQYELL (bLf222–230) and EDLIWK (bLf264–269) 
was effective. Considering their molecular mass, these peptides showed a much lower 
antiviral activity than that displayed by undigested bLf and by the fraction 1-280. Interestingly, 
these small peptides did not display any antiviral activity when they were separately tested.  
www.intechopen.com
  
Herpesviridae – A Look into This Unique Family of Viruses 
 
306 
It is important to note that effective fraction 1–280 contains both amino acid sequences of the 
two small co-purified peptides (amino acid sequences 222– 230 and 264–269), while 
ineffective fraction 86–258 does not contain the amino acid sequence 264–269 (Siciliano et al., 
1999). In the three-dimensional structure of iron-saturated bLf, these two small peptides are 
exposed to the solvent at the bLf surface and are located at opposite sites of the N-lobe 
(belonging to N2 and N1 domains respectively) (Moore et al., 1997). The markedly reduced 
antiviral activity displayed by the two associated peptides (amino acid sequences 222–230 
and 264–269) could therefore be correlated with the lack of the correct folding when they are 
separated from the protein.  
All together, these results suggest that in bovine lactoferrin, both amino acid sequences and 
their conformations are involved in protection form HSV-1 infection (Siciliano et al., 1999). 
Therefore it was concluded that the cluster of positive charges present in bLf has to be 
considered to be crucial for anti-herpesvirus activity. Interestigly, it should be noted that the 
anti HSV-1 active fragments belonging to the N-lobe of bLf do not have anti-rotavirus 
activity, while other peptides, belonging to the C-lobe, possess anti-rotavirus activity. The 
antiviral activity of lactoferrin towards viruses belonging to different families appears, 
therefore to be due to specific, although different, mechanisms, depending on the inhibited 
virus (Superti et al., 2001) 
5. Antiviral activity of intact ovotransferrin 
Contrary to the antiviral activity of lactoferrin, the antiviral activity of ovotransferrin was 
not demonstrated until a model of chicken embryo fibroblasts infected with Marek’s Disease 
Virus (MDV) was used (Giansanti et al., 2002).  
MDV belongs to the Herpesviridae family, and is currently grouped within the 
Alphaherpersvirinae subfamily, together with the herpesvirus of turkey (HVT) (Calnek, 2001). 
It possesses a 166–184 kb, double-stranded DNA genome. Like many herpesviruses (Izumiya et 
al., 2001), MDV is highly cell-associated. MDV infection of susceptible cells is generally 
cytocidal, but latency can also be established. The virus-induced pathological changes, known 
as the cytopathic effect (CPE), take place in both the cytoplasm and the nucleus when the lytic 
cycle is ongoing. MDV has been shown to induce the synthesis of ovotransferrin in infected 
chicken embryo fibroblasts (Morgan et al., 2001).  In chicken embryo fibroblast primary cultures, 
Otrf is effective in inhibiting infection by the herpesvirus of Marek disease. In this experimental 
avian herpes virus system, Otrf was more active than bLf or hLf. As already shown in human 
HSV model (Marchetti et al., 1996), iron saturation of the proteins did not influence the 
inhibiting activity of the iron-binding proteins, even though it could be expected that conditions 
increasing iron availability may facilitate virus infection since this metal ion is essential for 
nucleic acids and protein synthesis. These similarities suggested that Otrf inhibits MDV 
replication in a way similar to that utilized by hLf and bLf in inhibiting HSV-1 replication.  
5.1 Antiviral activity of ovotransferrin peptides 
Like lactoferrin, Otrf displays antiviral activity, though only when tested in homologous cell 
systems using primary cultures of chicken embryo fibroblasts infected with Marek’s disease 
virus. Lactoferricin B (bovine lactoferrin fragment bLf17–41) and two peptides, derived from the 
tryptic digestion of bLf, fragments ADRDQYELL (bLf222–230) and EDLIWK (bLf264–269), have 
been found to display antiviral activity towards herpes simplex virus (Siciliano  et al.,   1999), 
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although, the antiviral activity of lactoferricin B and of these two other peptides was much 
lower than that of the intact protein, and this was tentatively attributed to the lack of correct 
folding of such fragments when they are separated from the protein. Therefore, fragments in 
hOtrf having sequence and/or structural homologies with the fragments with antiviral activity 
found in bLf were identified and tested for their antiviral activity with the aim of evaluating 
their possible involvement in the antiviral activity of the intact ovotransferrin.  No fragment 
was identified in hOtrf having sequence homology with bLf fragment lactoferricin B (bLf17–41). 
On the contrary, two fragments having sequence homology with bLf fragments ADRDQYELL 
(bLf222–230) and EDLIWK (bLf264–269) were identified in hOtrf. The first one was the 
fragment DQKDEYELL (hOtrf219-227), while the second one was the fragment KDLLFK. 
Interestingly, the latter fragment KDLLFK is repeated twice in hOtrf, both in N-lobe (hOtrf269–
361) and in C-lobe (hOtrf633–638). Moreover, hOtrf fragments DQKDEYELL and KDLLFK are 
located at the surface of the protein. As concerning structural homologies in the intact proteins, 
the hOtrf fragment KDLLFK possesses into the intact hOtrf a conformation similar to that 
possessed by the fragment EDLIWK in intact bLf (see figure 3). Similarly, the fragment 
LQMDDFELL (hOtrf561–569) displays the greatest structural homology in intact hOtrf with the 
fragments ADRDQYELL into intact bLf (see figure 3).  
 
 
PANEL A: Fragment ADRDQYELL (bLf222–230),  
PANEL B: Fragment DQKDEYELL (hOtrf219-227)  
PANEL C: Fragment EDLIWK (bLf264–269)  
PANEL D: Fragment KDLLFK (hOtrf269–361 and hOtrf633–638). 
The fragments are shown with the conformation they have in the intact proteins: bovine lactoferrin 
(bLf) and hen’s ovotransferrin (hOTrf). The ribbons indicate the presence of alpha-elices. In Panel A, the 
arrow indicates a.a. sequence direction. The colors indicate aminoacid properties: Green: hydrophobic; 
Blue: negatively charged; Red: positively charged; White: polar. 
Molecular graphics images were produced using the UCSF chimera package (Pettersen et al., 2004) 
Fig. 3. Lactoferrin and ovotransferrin fragments with anti-herpesvirus activity 
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However, NMR spectroscopy indicated that, as expected, all these peptides do not have a 
favourite conformation in solution, as they are too short to have any secondary structure. 
All the fragments were then chemically synthesized and the corresponding peptides were 
tested on CEF/ MDV system for their cytotoxic and antiviral activities, hOtrf and bLf being 
used as positive control proteins. The peptide LNNSRA, with no sequence or structural 
homologies, was used as negative control. The maximal antiviral activities were shown by 
the positive control intact proteins (hOtrf and bLf) and no antiviral activity was shown by 
the negative control peptide LNNSRA. The peptides LQMDDFELL (hOtrf561–569) and 
KDCIIK (hOtrf378–383), which have little or no sequence homologies with the 
corresponding bLf fragment despite structural homologies in the intact proteins, showed 
little or no antiviral activity. On the contrary, the peptides in hOtrf having greatest sequence 
homology, DQKDEYELL (hOtrf219–227) and KDLLFK (hOtrf269–361 and hOtrf633–638), 
with the bLf peptides with antiviral activity ADRDQYELL (bLf222–230) and EDLIWK 











hOtrf fragment with sequence homology 
with bLf222-230 
≥ 125 * 
EDLIWK (bLf264-269) 
Control Blf fragment with antiviral 
activity 
≥ 20 
KDLLFK (Otrf269-361) and 
(Otrf633-638) 
hOtrf fragment with sequence homology 
with bLf264-269 
≥ 40 * 
LNNSRA negative control 1 
Hen Ovotransferrin positive control ≥ 1600 
Bovine lactoferrin positive control ≥ 1000 
Selectivity index (SI) is expressed as the ratio between the effective dose required to inhibit fluorescence 
by 50% and the effective dose required for 50 % cytotoxicity. Statistically significant differences (P < 
0.05) of the hOtrf fragment selectivity index as compared with that of the corresponding bLf fragment. 
Table 1. Bovine lactoferrin and hen ovotransferrin fragments: Characteristics and Selectivity 
Index (SI) towards Marek Disease Virus (modified from Giansanti et al., 2002). 
The antiviral activities of these two hOtrf peptides were about the double of those shown by 
the corresponding bLf derived peptides with sequence homologies. It is worth noting that 
these two hOtrf fragments possess significant antiviral activity such as the corresponding 
homologous fragments in bLf, suggesting that these fragments could indeed have a role in 
the exploitation of antiviral activity towards herpes viruses of those proteins when they are 
in native conformation. However, the presence of hydrophobic and positively charged 
residues is possibly a condition needed but not sufficient for the antiviral activity of bLf and 
hOtrf derived peptides, since the conformations they assume in the intact proteins may also 
be required (Giansanti et al., 2005) 
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The results reported here suggest that clusters of positive charges present in the N-lobe of 
both bovine lactoferrin and hen’s ovotransferrin are the most responsible for the anti-
herpesvirus activity. The antiviral activity of these proteins is exerted at a very early stage in 
the viral multiplication cycle, possibly by interference at the virus-cell interface by binding 
to cell surface glycosaminoglycans. Few protein short peptides display anti-herpesviridae 
activity, although hundreds-fold less than the intact proteins, indicating that, for the 
exploitation of the maximal antiviral activity, the correct folding of aminoacids containing 
these clusters of positive charges is also required.  
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